Business
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.","length":412,"tagName":"p"},{"type":"image","alt":"Logo for PharmaLogic Holdings Corporation.","displaySize":"","headline":null,"caption":"Logo for PharmaLogic Holdings Corporation.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":196,"url":"https://media.zenfs.com/en/prnewswire.com/122c723eb152c9044c0ec170dee060ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a6oq9yG7oOdxJoAD0x2n1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/122c723eb152c9044c0ec170dee060ed","width":400,"height":196}},"href":"https://mma.prnewswire.com/media/2700185/PharmaLogic_Holdings_Corp_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across global markets. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus (NASDAQ: LNTH), GE HealthCare (NASDAQ: GEHC) and Ipsen (EURONEXT: IPN).","length":356,"tagName":"p"},{"type":"text","content":"Steve Chilinski, who has led the company through 13 years of exceptional growth, retired as Chief Executive Officer on June 1, 2025, and will assume the role of Executive Chairman of the Board.","length":193,"tagName":"p"},{"type":"text","content":""I'm grateful to Steve and the Board for their trust and their confidence in PharmaLogic's future," said Etienne Montagut. "The company has experienced great success, and I'm very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies."","length":416,"tagName":"p"},{"type":"text","content":"About PharmaLogic Holdings Corp.","length":32,"tagName":"p"},{"type":"text","content":"Ph...